2012
DOI: 10.1038/nature11412
|View full text |Cite
|
Sign up to set email alerts
|

Comprehensive molecular portraits of human breast tumours

Abstract: Summary We analyzed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, mRNA arrays, microRNA sequencing and reverse phase protein arrays. Our ability to integrate information across platforms provided key insights into previously-defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, P… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

343
7,427
23
26

Year Published

2013
2013
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 10,179 publications
(8,024 citation statements)
references
References 56 publications
343
7,427
23
26
Order By: Relevance
“…Basal-like and Human Epidermal Growth Factor Receptor 2-Enriched (HER2E) breast cancers had the highest TMB (TMB-Hi fraction, 37% and 38%, respectively) while Luminal A (LumA) tumors had the lowest TMB, with only 11.5% in the TMB-Hi fraction (Figure 3A) consistent with previous findings. 22 Among all tumors designated TMB-Hi, the FID subclass represented 44 women who exhibited a high OS rate of 100% at 10 years (Figure 1C); 66% of this excellent-outcome subclass was comprised of the more clinically aggressive subtypes: Basal-like, HER2E and Luminal B (LumB) (Figure 3B). Among the four major subtypes, LumA tumors comprised the majority of the TCGA cohort (53%; n = 495), with 88.5% of LumA tumors classifying with the TMB-Lo group.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Basal-like and Human Epidermal Growth Factor Receptor 2-Enriched (HER2E) breast cancers had the highest TMB (TMB-Hi fraction, 37% and 38%, respectively) while Luminal A (LumA) tumors had the lowest TMB, with only 11.5% in the TMB-Hi fraction (Figure 3A) consistent with previous findings. 22 Among all tumors designated TMB-Hi, the FID subclass represented 44 women who exhibited a high OS rate of 100% at 10 years (Figure 1C); 66% of this excellent-outcome subclass was comprised of the more clinically aggressive subtypes: Basal-like, HER2E and Luminal B (LumB) (Figure 3B). Among the four major subtypes, LumA tumors comprised the majority of the TCGA cohort (53%; n = 495), with 88.5% of LumA tumors classifying with the TMB-Lo group.…”
Section: Resultsmentioning
confidence: 99%
“…22,23 We hypothesized that TMB, as a quantifier of tumor antigenicity, may influence the prognostic power of the immune subclasses. We posited that a better understanding of the relationship between TMB and the prognostic potential of the immune subclasses could allow one to distinguish tumors inherently vulnerable to immune rejection from those that escape immune recognition by exclusion of immune cells and/or failure to elicit a protective immune response.…”
Section: Introductionmentioning
confidence: 99%
“…We used TCGA's BC cohort (Cancer Genome Atlas Network, 2012), n  = 1052, to assess the expression pattern of genes of interest in different subtypes of BC. Gene expression was assayed by RNA sequencing, RSEM (RNAseq by Expectation‐Maximization; Li et al ., 2010) normalized per gene.…”
Section: Methodsmentioning
confidence: 99%
“…Breast neoplasms is a common disease in women and also a serious threat to the health of women 49, 50. In the early years, the mortality of breast neoplasms is just inferior to lung neoplasms.…”
Section: Resultsmentioning
confidence: 99%